Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome
Authors
Keywords
Hepatocellular carcinoma, Adverse events, Computed axial tomography, Lesions, Metastasis, Cancer treatment, Portal veins, Thrombosis
Journal
PLoS One
Volume 15, Issue 4, Pages e0231427
Publisher
Public Library of Science (PLoS)
Online
2020-04-11
DOI
10.1371/journal.pone.0231427
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Impact of ALBI grade on survival in patients with HCC who received sorafenib: an analysis using time‐dependent ROC
- (2018) Toshifumi Tada et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
- (2017) Atsushi Hiraoka et al. Liver Cancer
- Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2015) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
- (2015) Bruno Vincenzi et al. PLoS One
- Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
- (2014) Tadaaki Arizumi et al. DIGESTIVE DISEASES
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
- (2014) M. Ronot et al. ONCOLOGIST
- Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSGJ
- (2014) Tadaaki Arizumi et al. ONCOLOGY
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
- (2014) Masatoshi Kudo et al. Liver Cancer
- Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update
- (2012) Shuichi Kaneko et al. HEPATOLOGY RESEARCH
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma
- (2011) Yukinori Imai et al. JOURNAL OF GASTROENTEROLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now